
Scott Kaatz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3870518/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk factors and outcomes associated with community-onset and hospital-acquired coinfection in patients hospitalized for coronavirus disease 2019 (COVID-19): A multihospital cohort study. Infection Control and Hospital Epidemiology, 2022, 43, 1184-1193.	1.0	12
2	COVID-19 risk index (CRI): a simple and validated emergency department risk score that predicts mortality and the need for mechanical ventilation. Journal of Thrombosis and Thrombolysis, 2022, 53, 567-575.	1.0	4
3	Management Strategies Following Slightly Out of Range INRs: Watchful Waiting vs. Dose Changes. Blood Advances, 2022, , .	2.5	Ο
4	Impact of Early Corticosteroids on Preventing Clinical Deterioration in Non-critically Ill Patients Hospitalized with COVID-19: A Multi-hospital Cohort Study. Infectious Diseases and Therapy, 2022, 11, 887-898.	1.8	5
5	Association of adding antiplatelet therapy to warfarin for management of venous thromboembolism with bleeding and other adverse events. Vascular Medicine, 2022, 27, 382-384.	0.8	2
6	Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis, 2022, 54, 197-210.	1.0	29
7	Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked versed venous thromboembolism. Blood Advances, 2022, 6, 4605-4616.	2.5	7
8	Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations. JAMA Network Open, 2022, 5, e2222089.	2.8	3
9	ISTH guidelines for antithrombotic treatment in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2022, 20, 2214-2225.	1.9	100
10	Unprotected discharge: absence of stroke prevention strategies in patients with atrial fibrillation admitted for bleeding. Journal of Interventional Cardiac Electrophysiology, 2021, 62, 337-346.	0.6	1
11	Leadership & Professional Development: Lessons Learned From the Other Side of the Stethoscope (and) Tj ETQ	1 1 <mark>0 7</mark> 84 1	314 rgBT /O
12	Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19. JAMA Network Open, 2021, 4, e2111788.	2.8	43
13	Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication. JAMA Internal Medicine, 2021, 181, 817.	2.6	33
14	Comparison of temporary interruption with continuation of direct oral anticoagulants for low bleeding risk procedures. Thrombosis Research, 2021, 203, 27-32.	0.8	5
15	Derivation and external validation of a simple risk score to predict in-hospital mortality in patients hospitalized for COVID-19. Medicine (United States), 2021, 100, e27422.	0.4	3
16	Standard Versus Higher Intensity Anticoagulation for Patients With Mechanical Aortic Valve Replacement and Additional Risk Factors for Thromboembolism. American Journal of Cardiology, 2021, 159, 100-106.	0.7	1
17	Extended Thromboprophylaxis in Patients with COVID-19. Blood, 2021, 138, 1065-1065.	0.6	0
18	Outcomes of Direct Oral Anticoagulants with Aspirin Versus Warfarin with Aspirin for Atrial Fibrillation and/or Venous Thromboembolic Disease. Blood, 2021, 138, 179-179.	0.6	0

#	Article	IF	CITATIONS
19	Perioperative consultative hematology: can you clear my patient for a procedure?. Hematology American Society of Hematology Education Program, 2021, 2021, 521-528.	0.9	2
20	Contemporary NSTEMI management: the role of the hospitalist. Hospital Practice (1995), 2020, 48, 1-11.	0.5	9
21	Perioperative management of anticoagulation. Hospital Practice (1995), 2020, 48, 231-240.	0.5	3
22	COVID-19 versus HIT hypercoagulability. Thrombosis Research, 2020, 196, 38-51.	0.8	37
23	Extended Venous Thromboembolism Prophylaxis in Medically III Patients: An NATF Anticoagulation Action Initiative. American Journal of Medicine, 2020, 133, 1-27.	0.6	18
24	Treatment of Acute Venous Thromboembolism. Medical Clinics of North America, 2020, 104, 631-646.	1.1	0
25	Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registryâ€based cohort study. Journal of Thrombosis and Haemostasis, 2020, 18, 2025-2030.	1.9	6
26	Surgical venous thromboembolism prophylaxis: clinical practice update. Hospital Practice (1995), 2020, 48, 248-257.	0.5	10
27	"Reduce the Likelihood of Patient Harm Associated with the Use of Anticoagulant Therapyâ€ Commentary from the Anticoagulation Forum on the Updated Joint Commission NPSG.03.05.01 Elements of Performance. Joint Commission Journal on Quality and Patient Safety, 2020, 46, 173-180.	0.4	7
28	Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series. Journal of Thrombosis and Thrombolysis, 2020, 50, 844-848.	1.0	7
29	Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis, 2020, 50, 72-81.	1.0	362
30	Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2019, 48, 500-505.	1.0	5
31	Missed opportunities to prevent upper GI hemorrhage: The experience of the Michigan Anticoagulation Quality Improvement Initiative. Vascular Medicine, 2019, 24, 153-155.	0.8	9
32	Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. JAMA Internal Medicine, 2019, 179, 533.	2.6	37
33	Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. American Journal of Hematology, 2019, 94, 697-709.	2.0	225
34	Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia. Annals of Internal Medicine, 2019, 171, 153.	2.0	140
35	Sarcoidosis presenting as facial and scalp ulceration with secondary bacterial infection of the skin. BMJ Case Reports, 2019, 12, e231769.	0.2	0
36	Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication. Blood, 2019, 134, 787-787.	0.6	3

#	Article	IF	CITATIONS
37	A Multi-Center Quality Improvement Intervention to Reduce the Inappropriate Use of Aspirin Among Patients Anticoagulated with Warfarin for Atrial Fibrillation or Venous Thromboembolism. Blood, 2019, 134, 788-788.	0.6	0
38	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood, 2018, 131, 2151-2160.	0.6	62
39	Mind the gap: results of a multispecialty survey on coordination of care for peri-procedural anticoagulation. Journal of Thrombosis and Thrombolysis, 2018, 45, 403-409.	1.0	4
40	Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation. Current Medical Research and Opinion, 2018, 34, 275-284.	0.9	1
41	Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 58-68.	1.0	7
42	CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge. Current Medical Research and Opinion, 2018, 34, 1967-1974.	0.9	0
43	Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-Worldâ€-Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials. Journal of Thrombosis and Thrombolvsis. 2018. 46. 316-324.	1.0	11
44	Patterns and Predictors of Shortâ€Term Peripherally Inserted Central Catheter Use: A Multicenter Prospective Cohort Study. Journal of Hospital Medicine, 2018, 13, 76-82.	0.7	29
45	Patterns and Predictors of Peripherally Inserted Central Catheter Occlusion: The 3P-O Study. Journal of Vascular and Interventional Radiology, 2017, 28, 749-756.e2.	0.2	36
46	Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation. JAMA Cardiology, 2017, 2, 341.	3.0	1
47	Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants. Current Cardiology Reports, 2017, 19, 124.	1.3	21
48	Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. Clinical Therapeutics, 2017, 39, 1396-1408.	1.1	6
49	Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. Journal of Thrombosis and Thrombolysis, 2017, 43, 283-288.	1.0	22
50	Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. Blood Advances, 2017, 1, 2536-2540.	2.5	7
51	Reversing factor Xa inhibitors – clinical utility of andexanet alfa. Journal of Blood Medicine, 2017, Volume 8, 141-149.	0.7	44
52	Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics. Implementation Science, 2017, 12, 87.	2.5	18
53	Spontaneous Thyroid Hemorrhage on Chronic Anticoagulation Therapy. Clinics and Practice, 2017, 7, 932.	0.6	9
54	Rectus Sheath Hematoma Associated with Apixaban. Clinics and Practice, 2017, 7, 957.	0.6	7

#	Article	IF	CITATIONS
55	Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. American Journal of Medicine, 2016, 129, 1001.e9-1001.e18.	0.6	69
56	Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant. Journal of Thrombosis and Thrombolysis, 2016, 42, 566-572.	1.0	6
57	Preclinical and clinical data for factor Xa and "universal―reversal agents. American Journal of Emergency Medicine, 2016, 34, 39-45.	0.7	16
58	Preclinical and Clinical Data for Factor Xa and "Universal―Reversal Agents. American Journal of Medicine, 2016, 129, S80-S88.	0.6	23
59	Bridging Anticoagulation Before Colonoscopy. JAMA Cardiology, 2016, 1, 1076.	3.0	9
60	Variations in Peripherally Inserted Central Catheter Use and Outcomes in Michigan Hospitals. JAMA Internal Medicine, 2016, 176, 548.	2.6	42
61	Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 187-205.	1.0	93
62	A Comparison of Socioeconomic Factors in Patients Continuing Warfarin Versus Those Transitioning to Direct Oral Anticoagulants (DOACs) for Venous Thromboembolic Disease or Atrial Fibrillation. Blood, 2016, 128, 1179-1179.	0.6	1
63	Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism. Blood, 2016, 128, 139-139.	0.6	3
64	Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease?. Blood, 2016, 128, 272-272.	0.6	0
65	Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients. Blood, 2016, 128, 144-144.	0.6	2
66	Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care. International Journal of General Medicine, 2015, 8, 283.	0.8	10
67	The changing characteristics of atrial fibrillation patients treated with warfarin. Journal of Thrombosis and Thrombolysis, 2015, 40, 488-493.	1.0	4
68	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. New England Journal of Medicine, 2015, 373, 823-833.	13.9	951
69	Integrating Electronic Health Records in the Delivery of Optimized Anticoagulation Therapy. Annals of Pharmacotherapy, 2015, 49, 125-126.	0.9	0
70	Stroke Prevention in Patients With Atrial Fibrillation and Renal Dysfunction. Stroke, 2014, 45, 2497-2505.	1.0	13
71	How to Develop and Validate Institutional ACS Protocols: Guidelines and Transitions of Care in ACS Management. Current Emergency and Hospital Medicine Reports, 2014, 2, 69-75.	0.6	0
72	Rationale for Upstream Dual Antiplatelet Therapy in Non-ST-Segment Elevation Myocardial Infarction. Current Emergency and Hospital Medicine Reports, 2014, 2, 76-89.	0.6	1

#	Article	IF	CITATIONS
73	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet, The, 2014, 383, 880-888.	6.3	425
74	Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice. Thrombosis Research, 2014, 134, 807-813.	0.8	14
75	The Predictive Ability of the CHADS2 and CHA2DS2-VASc Scores for Bleeding Risk in Atrial Fibrillation: The MAQI2 Experience. Thrombosis Research, 2014, 134, 294-299.	0.8	35
76	Reversal of target-specific oral anticoagulants. Journal of Thrombosis and Thrombolysis, 2013, 36, 195-202.	1.0	36
77	New Oral Anticoagulants. Hospital Medicine Clinics, 2013, 2, e456-e471.	0.2	0
78	Top practice-changing articles over the last two years. Journal of Thrombosis and Thrombolysis, 2013, 35, 325-332.	1.0	1
79	Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study. Blood, 2013, 122, 36-36.	0.6	3
80	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. Blood, 2013, 122, 460-460.	0.6	2
81	Diagnosis and Treatment of Venous Thromboembolic Disease. , 2013, , 755-764.		1
82	The Effectiveness Of 30-40 Mm Hg Compression Stockings To Treat Acute Leg Pain Associated With Proximal Deep Vein Thrombosis: Results From The Sox Randomized Controlled Trial. Blood, 2013, 122, 1126-1126.	0.6	0
83	Reply to Letters Regarding Article, "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial― Circulation, 2012, 125, .	1.6	2
84	Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. American Journal of Hematology, 2012, 87, S141-5.	2.0	320
85	A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The S.O.X. Trial. Blood, 2012, 120, 393-393.	0.6	5
86	Update in bridging anticoagulation. Journal of Thrombosis and Thrombolysis, 2011, 31, 259-264.	1.0	30
87	Venous Thromboembolism Prophylaxis After Hospital Discharge: Transition to Preventive Care. Hospital Practice (1995), 2011, 39, 7-15.	0.5	6
88	Perioperative Heparin Bridging in Patients Receiving Oral Anticoagulation: Meta-Analysis of Bleeding and Thromboembolic Rates. Blood, 2011, 118, 545-545.	0.6	1
89	Venous thromboembolism: What to do after anticoagulation is started. Cleveland Clinic Journal of Medicine, 2011, 78, 609-618.	0.6	9
90	Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin for Elective Surger or Procedure - the BRIDGE Trial: Design, Rationale and Clinical Implications. Blood, 2011, 118, 4327-4327.	0.6	0

#	Article	IF	CITATIONS
91	Impact on patient care: patient case through the continuum of care. Journal of Thrombosis and Thrombolysis, 2010, 29, 167-170.	1.0	2
92	What you should know about the 2008 American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th) on Antithrombotic and Thrombolytic Therapy. Journal of Thrombosis and Thrombolysis, 2010, 29, 219-226.	1.0	0
93	Systematic Review to Identify Validated Manual Warfarin Maintenance Dosing Tools Blood, 2010, 116, 3800-3800.	0.6	1
94	Duration of anticoagulation treatment in patients with venous thromboembolism. Journal of the American Osteopathic Association, The, 2010, 110, 638-44.	1.7	1
95	Determinants and measures of quality in oral anticoagulation therapy. Journal of Thrombosis and Thrombolysis, 2008, 25, 61-66.	1.0	55
96	Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy. Thrombosis Journal, 2008, 6, 6.	0.9	44
97	Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control. Archives of Internal Medicine, 2007, 167, 239.	4.3	527
98	Outcomes for Ximelagatran Compared with Warfarin According to INR Control: Results from SPORTIF III and V Atrial Fibrillation Trials Blood, 2005, 106, 902-902.	0.6	1
99	Ardeparin plus graduated compression stockings prevented DVT after knee surgery. ACP Journal Club, 1996, 125, 63.	0.1	Ο